Intensity Therapeutics Files Definitive Proxy Statement

TL;DR

INTENSITY THERAPEUTICS (INTT) filed its proxy statement for the annual meeting. Vote your shares!

AI Summary

Intensity Therapeutics, Inc. filed a definitive proxy statement on June 4, 2024, for its annual meeting. The filing outlines the proposals to be voted on by shareholders, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is seeking shareholder approval for these routine corporate governance matters.

Why It Matters

This filing is crucial for shareholders as it details the agenda for the annual meeting and provides information necessary for them to cast informed votes on company leadership and financial oversight.

Risk Assessment

Risk Level: low — This is a routine DEF 14A filing for a proxy statement, which is standard corporate procedure and does not inherently introduce new financial risks.

Key Players & Entities

• INTENSITY THERAPEUTICS, INC. (company) — Registrant
• 0001567264-24-000031.txt (document) — Filing document identifier
• 20240604 (date) — Filing date

FAQ

Filing Documents

• intensity-proxystatement20.htm (DEF 14A) — 406KB
• a1.jpg (GRAPHIC) — 1KB
• intensitytherapeuticsincpr.jpg (GRAPHIC) — 430KB
• intensitytherapeuticsincpra.jpg (GRAPHIC) — 174KB
• signaturelewishbender.jpg (GRAPHIC) — 42KB
• 0001567264-24-000031.txt ( ) — 1298KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 MANAGEMENT AND CORPORATE GOVERNANCE 10 EXECUTIVE OFFICER AND DIRECTOR COMPENSATION 16 EQUITY COMPENSATION PLAN INFORMATION 24 REPORT OF AUDIT COMMITTEE 25 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 26 PROPOSAL NO. 1 ELECTION OF DIRECTORS 28 PROPOSAL NO. 2 APPROVAL OF THE COMPANY'S 2024 EMPLOYEE STOCK PURCHASE PLAN 29 PROPOSAL NO. 3 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 32 CODE OF CONDUCT AND ETHICS 34 OTHER MATTERS 34 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 34 Appendices Appendix A i Intensity Therapeutics, Inc. 1 Enterprise Drive, Suite 430 Shelton, CT 06484 PROXY STATEMENT FOR INTENSITY THERAPEUTICS, INC. 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JULY 17, 2024 This proxy statement, along with the accompanying notice of 2024 annual meeting of stockholders, contains information about the 2024 annual meeting of stockholders of Intensity Therapeutics, Inc., including any adjournments or postponements of the annual meeting. We are holding the annual meeting at 1030 a.m., Eastern Time, on Wednesday, July 17, 2024, virtually at www.virtualshareholdermeeting.comINTS2024. In this proxy statement, we refer to Intensity Therapeutics, Inc. as "Intensity," "the Company," "we" and "us." This proxy statement relates to the solicitation of proxies by our board of directors for use at the annual meeting. On or about June 4, 2024, we intend to begin sending to our stockholders the Important Notice Regarding the Availability of Proxy Materials containing instructions on how to access our proxy statement for our 2024 annual meeting of stockholders and our 2023 annual report to stockholders. 1 IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JULY 17, 2024 This proxy statement, the notice of 2024 annual meeting of stockholders, our form of proxy c

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth certain information with respect to the beneficial ownership of our common stock as of May 31, 2024 for (a) the executive officers named in the Summary Compensation Table included elsewhere in this proxy statement, (b) each of our directors and director nominees, (c) all of our current directors and executive officers as a group and (d) each stockholder known by us to own beneficially more than 5% of our common stock. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. We deem shares of common stock that may be acquired by an individual or group within 60 days of May 31, 2024 pursuant to the exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of such individual or group, but those shares are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of common stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 13,711,877 shares of common stock outstanding on May 31, 2024. Shares Beneficially Owned Name and Address** Number Percent 5% Stockholders Leonard Batterson (1) 2,476,213 18.0 % Craig J. Duchossois (2) 1,053,753 7.7 % Lawrence F. Levy (3) 745,872 5.4 % Named Executive Officers and Directors Lewis H. Bender (4) 2,394,775 17.0 % Joseph Talamo - - John Wesolowski (5) 69,754 *

View Full Filing

View this DEF 14A filing on SEC EDGAR